DE69708919T2 - Neue liposomkomplexe mit erhöhter systemischer verabreichung - Google Patents

Neue liposomkomplexe mit erhöhter systemischer verabreichung

Info

Publication number
DE69708919T2
DE69708919T2 DE69708919T DE69708919T DE69708919T2 DE 69708919 T2 DE69708919 T2 DE 69708919T2 DE 69708919 T DE69708919 T DE 69708919T DE 69708919 T DE69708919 T DE 69708919T DE 69708919 T2 DE69708919 T2 DE 69708919T2
Authority
DE
Germany
Prior art keywords
liposomes
expression
highly efficient
liposome complexes
systemic administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69708919T
Other languages
English (en)
Other versions
DE69708919D1 (de
Inventor
Nancy Smyth-Templeton
N Pavlakis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Health NIH
Original Assignee
National Institutes of Health NIH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Health NIH filed Critical National Institutes of Health NIH
Application granted granted Critical
Publication of DE69708919D1 publication Critical patent/DE69708919D1/de
Publication of DE69708919T2 publication Critical patent/DE69708919T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
DE69708919T 1996-08-19 1997-08-01 Neue liposomkomplexe mit erhöhter systemischer verabreichung Expired - Lifetime DE69708919T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2438696P 1996-08-19 1996-08-19
PCT/US1997/013599 WO1998007408A1 (en) 1996-08-19 1997-08-01 Novel liposome complexes for increased systemic delivery

Publications (2)

Publication Number Publication Date
DE69708919D1 DE69708919D1 (de) 2002-01-17
DE69708919T2 true DE69708919T2 (de) 2002-06-27

Family

ID=21820321

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69708919T Expired - Lifetime DE69708919T2 (de) 1996-08-19 1997-08-01 Neue liposomkomplexe mit erhöhter systemischer verabreichung

Country Status (8)

Country Link
US (1) US6413544B1 (de)
EP (1) EP0955999B1 (de)
JP (1) JP4203835B2 (de)
AT (1) ATE209902T1 (de)
AU (1) AU730771B2 (de)
CA (1) CA2263705C (de)
DE (1) DE69708919T2 (de)
WO (1) WO1998007408A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288266B2 (en) * 1996-08-19 2007-10-30 United States Of America As Represented By The Secretary, Department Of Health And Human Services Liposome complexes for increased systemic delivery
AUPQ002399A0 (en) * 1999-04-28 1999-05-20 Australian National University, The Model membrane systems
EP1754488A1 (de) 1999-05-24 2007-02-21 Introgen Therapeutics, Inc. Verfahren und Zusammensetzungen für nichtvirale Gentherapie zur Behandlung von hyperproliferativen Krankheiten
ATE340560T1 (de) * 1999-05-24 2006-10-15 Introgen Therapeutics Inc Verfahren und zusammensetzungen für nichtvirale gentherapie zur behandlung von hyperproliferativen krankheiten
TR199901199A2 (xx) * 1999-05-31 2001-09-21 Kocagöz Tanil Bakteri transformasyon kiti
AUPQ259399A0 (en) 1999-09-01 1999-09-23 Lustre Investments Pte Ltd Therapeutic agents
US10293056B1 (en) * 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US6477426B1 (en) * 2000-06-20 2002-11-05 Celsion Corporation System and method for heating the prostate gland to treat and prevent the growth and spread of prostate tumors
US7037520B2 (en) 2002-03-22 2006-05-02 Baylor College Of Medicine Reversible masking of liposomal complexes for targeted delivery
US20040082521A1 (en) * 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
US20060003316A1 (en) * 2002-07-15 2006-01-05 John Simard Immunogenic compositions derived from poxviruses and methods of using same
US20040048260A1 (en) * 2002-09-10 2004-03-11 Fu-Hsiung Chang Transfection of nucleic acid
EP1585504A4 (de) * 2002-11-06 2009-07-15 Azaya Therapeutics Inc Proteinstabilisierte liposomale formulierungen pharmazeutischer wirkstoffe
WO2004104032A2 (en) 2003-05-14 2004-12-02 The University Of Iowa Research Foundation Methods and compositions related to high-titer pseudotyped retroviruses
CA2548220A1 (en) 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
EP1761248B1 (de) 2004-03-19 2012-05-23 Rodos BioTarget GmbH Kohlehydrat-derivatisierte liposome gegen zelluläre kohlehydrat-erkennungsdomänen von ctl/ctld-lektinen und intrazelluläre freisetzung von therapeutischen wirkverbindungen
EP1957045A2 (de) 2005-03-14 2008-08-20 Board of Regents, The University of Texas System Bioaktive fus1-peptide und nanopartikel-polypeptid-komplexe
US20090305409A1 (en) * 2005-03-24 2009-12-10 National University Corporation Hokkaido University Liposome Capable of Effective Delivery of Given Substance Into Nucleus
EP1940355B1 (de) 2005-09-30 2012-12-19 Auburn University Nanoträger zur gezielten Freisetzung eines Wirkstoffs - enthaltend Ansammlungen von auf ein Ziel ausgerichteten Landschaftsphagenproteinen
EP1994043A4 (de) 2006-02-10 2009-05-20 Univ Cincinnati Phosphatasehemmer-protein 1 als regulator der herzfunktion
DK2009990T3 (en) 2006-04-07 2017-01-09 Univ Texas METHODS AND COMPOSITIONS RELATED TO adenoassociated VIRUSFAGPARTIKLER
WO2008077413A1 (es) 2006-12-22 2008-07-03 Soluciones Biotecnologicas Innovacion Ltda Vacunas adn en peces
WO2008097623A2 (en) * 2007-02-07 2008-08-14 Gradalis, Inc. Methods and compositions for modulating sialic acid production and treating hereditary inclusion body myopathy
CN101868180A (zh) 2007-10-09 2010-10-20 圣路易斯华盛顿州立大学 成像粒子
US9468607B2 (en) * 2007-10-09 2016-10-18 Washington University Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
CA2713232C (en) 2008-01-25 2020-05-05 P53, Inc. P53 biomarkers
US8563690B2 (en) * 2008-11-03 2013-10-22 The Board Of Trustees Of The University Of Illinois Modulation of platelet aggregation
US9409983B2 (en) 2009-07-23 2016-08-09 The Board Of Trustess Of The University Of Illinois Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
US9764043B2 (en) 2009-12-17 2017-09-19 Washington University Antithrombotic nanoparticle
US9808500B2 (en) 2009-12-17 2017-11-07 Washington University Antithrombotic nanoparticle
CN103096874A (zh) 2010-04-15 2013-05-08 华盛顿大学 前药组合物、前药纳米粒子及其使用方法
WO2012033953A1 (en) 2010-09-08 2012-03-15 Halozyme, Inc. Methods for assessing and identifying or evolving conditionally active therapeutic proteins
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
WO2012119095A1 (en) 2011-03-02 2012-09-07 Board Of Regents, The University Of Texas System Fus1/tusc2 therapies
US10040853B2 (en) 2011-09-09 2018-08-07 Fred Hutchinson Cancer Research Center Methods and compositions involving NKG2D inhibitors and cancer
CN104379602B (zh) 2012-03-08 2017-05-03 哈洛齐梅公司 具有条件活性的抗表皮生长因子受体抗体及其使用方法
CN110464709A (zh) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
ES2787198T3 (es) 2014-01-31 2020-10-15 Factor Bioscience Inc ARN sintético para su uso en el tratamiento de la epidermólisis ampollosa distrófica
WO2016131052A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
JP7014721B2 (ja) 2015-09-18 2022-02-01 ディーエヌエーアールエックス インビボでの核酸発現のためのシステム及び方法
US11594135B2 (en) 2015-11-02 2023-02-28 Memgen, Inc. Methods of CD40 activation and immune checkpoint blockade
CA3004530A1 (en) 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
WO2017216775A2 (en) 2016-06-16 2017-12-21 The Regents Of The University Of California Identification of factor that promotes human hsc self-renewal
JP7099967B2 (ja) 2016-07-01 2022-07-12 リサーチ ディベロップメント ファウンデーション 幹細胞由来移植片からの増殖性細胞の排除
CA3033788A1 (en) 2016-08-17 2018-02-22 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
JP7041136B2 (ja) 2016-10-12 2022-03-23 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム Tusc2免疫療法のための方法および組成物
CN110381997A (zh) 2016-12-12 2019-10-25 茂体外尔公司 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
JP2020511521A (ja) * 2017-03-23 2020-04-16 ディーエヌエーアールエックス in vivoでの核酸発現のためのシステム及び方法
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
KR20200135986A (ko) 2018-03-19 2020-12-04 멀티비르 인코포레이티드 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
US10945955B2 (en) * 2018-04-25 2021-03-16 University Of Massachusetts Artificial exosome composition and related methods
CN108653750B (zh) * 2018-06-01 2022-04-22 成都诺恩基因科技有限公司 包裹质粒dna的阳离子脂质体复合物
WO2020089841A1 (en) 2018-10-31 2020-05-07 Garcia Joe G N Biomarkers and methods of use for radiation-induced lung injury
MX2022001732A (es) 2019-08-12 2022-05-06 Purinomia Biotech Inc Metodos y composiciones para promover y potenciar la respuesta inmunitaria mediada por linfocitos t dirigida a la adcc de las celulas con expresion de cd39.
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之pd-l1結合多肽
WO2023057567A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Pd-l1 binding affimers
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5206027A (en) * 1990-09-13 1993-04-27 Fuji Photo Film Co., Ltd. Amphipathic compound and liposome comprising the same
CA2134773A1 (en) * 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy

Also Published As

Publication number Publication date
AU730771B2 (en) 2001-03-15
AU4050297A (en) 1998-03-06
EP0955999A1 (de) 1999-11-17
JP2000516630A (ja) 2000-12-12
ATE209902T1 (de) 2001-12-15
CA2263705C (en) 2007-12-04
US6413544B1 (en) 2002-07-02
JP4203835B2 (ja) 2009-01-07
WO1998007408A1 (en) 1998-02-26
EP0955999B1 (de) 2001-12-05
CA2263705A1 (en) 1998-02-26
DE69708919D1 (de) 2002-01-17
US20020028219A1 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
DE69708919D1 (de) Neue liposomkomplexe mit erhöhter systemischer verabreichung
Trubetskoy et al. Cationic liposomes enhance targeted delivery and expression of exogenous DNA mediated by N-terminal modified poly (L-lysine)-antibody conjugate in mouse lung endothelial cells
Kawakami et al. Asialoglycoprotein receptor-mediated gene transfer using novel galactosylated cationic liposomes
DE69906977D1 (de) In liposomen verkapselte nukleinsäurekomplexe
CA2270396A1 (en) Cationic reagents for transfection
EP0759694A4 (de) Verfahren zur in-vivo abgabe therapeutischer agenzien mittels liposomen
ATE362991T1 (de) Kondensierte plasmid-liposome komplex zur transfektion
ATE172636T1 (de) Liposomales verabreichungssystem für biologisch aktive stoffe
IL130823A0 (en) Peptide-lipid conjugates liposomes and liposomal drug delivery
DE69730218D1 (de) Fusogene liposomen
WO1997011682A3 (en) Emulsion and micellar formulations for the delivery of biologically active substances to cells
FI963103A (fi) Ei-virusvektori
ATE322255T1 (de) Polyamid-oligomere
DE69830249D1 (de) Zielgerichtete liposomen zur verabreichung von genen
AU4089899A (en) Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy
AU1776801A (en) Modular targeted liposomal delivery system
WO1999059643A3 (en) Liposomal delivery complex
EE200000102A (et) Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene
WO1999065461A3 (en) Cationic amphiphile micellar complexes
CO5280052A1 (es) Virosomas cationicos dosper
MX9708111A (es) Lipidos cationicos para terapia genica.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition